Sintilimab and Nab-paclitaxel in Second-line Treatment of Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma
Status:
Recruiting
Trial end date:
2022-10-30
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of Sintilimab (PD-1 inhibitor) and nab-paclitaxel in
second line treatment of advanced gastric and gastro-esophageal junction adenocarcinoma. This
is a prospective, multi-centers, single arm phase II trial with primary objective overall
response rate and second objective of safety and other efficacy endpoints.
Phase:
Phase 2
Details
Lead Sponsor:
Chinese Academy of Medical Sciences
Collaborators:
Beijing Friendship Hospital Beijing Hospital Chinese PLA General Hospital